Japanese Pharmaceutical Company Eisai Expands UK Site with New Facility

   Japanese Pharmaceutical Company Eisai Expands UK Site with New Facility

  PR Newswire

  HATFIELD, England, June 17, 2013

HATFIELD, England, June 17, 2013 /PRNewswire/ --

   New, high tech, global packaging facility for Eisai's investigational 
                           thyroid cancer treatment

Eisai today announces the expansion of its UK Hatfield based EMEA (Europe,
Middle East, Africa, Russia and Oceania) Knowledge Centre with an additional
high potency, global packaging capability. The new facility will primarily
handle the blister packaging of Eisai's investigational treatment lenvatinib
which is used to treat thyroid cancer as well as other types of solid tumours.
Once fully developed, the expanded Hatfield site will also increase capacity
to package and supply the anti-epilepsy drug (AED) Fycompa ^® (perampanel) and
other new products, to new markets around the world. 

 (Photo: http://photos.prnewswire.com/prnh/20130617/621582 )

The Hatfield site is the company's EMEA headquarters and is growing in
significance to Eisai's worldwide business as it serves as a global supply
centre for new products. Fycompa was jointly developed in Japan and the UK
and, as a result, Eisai is committed to a long-term global business structure
and investment into further research and development in the UK.

The construction of the new, two storey 2,900m ^2 packaging facility will
expand the current 7,800m ^2 Hatfield site by nearly 40%. The building works,
subject to planning permission, is scheduled to start in September 2013 and be
completed by mid-2014. This represents a foreign direct investment of over £8
million into the UK manufacturing industry. Eisai's planning submission
includes a forecasted potential employee increase in the next 5-7 years of up
to 40 new permanent personnel over the current staff of c.100 to service the
additional packaging capacity.

Responding to today's expansion announcement, Rt.  Hon. David Willetts ,
Minister for Universities and Science comments : "Eisai's decision to invest
is great news for the UK and reflects the Government's commitment to creating
the best environment for life sciences. It will build on the Hatfield site's
manufacturing capability, which I saw when I visited last year, and supports
highly skilled jobs."

Mr  Haruo Nai to , President and CEO , Eisai  co nfirms : "This new
investment is a vote of confidence in our EMEA Knowledge Centre and Hatfield
facility. The UK remains competitive as a location for advanced manufacturing
and I am delighted that we are now able to expand our global centre for
packaging at Hatfield, home to our EMEA sales and marketing, R&D, and
manufacturing operations."

Gary Hendler, President and CEO, Eisai EMEA explain s : "The purpose of this
direct investment in the company's EMEA Knowledge Centre in Hatfield is to
enhance our capability as a centre of packaging excellence for global supply
of our growing range of products. As we supply new and existing products to
an increasing number of countries with different languages, our packaging
capability needs to cope with an extremely high mix of low-volume packaging,
often difficult to handle compounds such as lenvatinib. Our expansion also
reaffirms Eisai's commitment to and recognition of the importance of the life
sciences industry in the UK today - we are proud that the UK has such a
pivotal role in this Japanese pharmaceutical company's commercial growth
strategy."

The expansion of this manufacturing centre underscores Eisai's human health
care mission, the company's commitment to increasing access to innovative
solutions in disease prevention, cure and care for the health and well-being
of people worldwide. Eisai is committed to addressing the unmet medical needs
of patients and their families.

Notes  to  Edi to rs:

Eisai has a long and established history of scientific investment and
partnership in the UK:

  *Eisai's first investments into UK R&D began 20 years ago with a landmark
    partnership with the neurosciences department at University College London
    (UCL), established to undertake world-leading scientific research into
    neurodegenerative diseases. This partnership continues to this day.
  *After entering a new phase in 2011, the company's Neuroscience Product
    Creation Unit (Neuroscience PCU) and UCL are currently engaging in joint
    research into neurodegenerative diseases, including biomarker research and
    drug discovery.
  *Eisai is committed to making further contributions to address key unmet
    medical needs in neurosciences by maintaining and strengthening the
    relationship built up with UCL, whilst at the same time leveraging the
    knowledge accumulated over the course of the partnership for the benefit
    of patients and their families in Europe and beyond.
  *Eisai established the £100 million EMEA Knowledge Centre (EKC), in June
    2009 in Hatfield Hertfordshire. This site integrates the company's
    discovery research, clinical development, production, marketing, and EMEA
    headquarters functions with the aim of expanding business operations
    further in Europe and around the world
  *In 2012, the Eisai Hatfield site became the first global, solid dose
    manufacture supply site outside of Japan for the antiepilepsy drug Fycompa
    (perampanel)
  *Eisai plans the construction of an additional high potency, global
    packaging capability to handle the blister packaging of Eisai's
    investigational treatment lenvatinib (E7080) and later the packaging of
    Fycompa and other products.

Eisai in Oncology

Our commitment to meaningful progress in oncology research, built on
scientific expertise, is supported by a global capability to conduct discovery
and preclinical research, and develop small molecules, therapeutic vaccines,
and biologic and supportive care agents for cancer across multiple
indications.

About Eisai EMEA in Epilepsy

Eisai is committed to developing and delivering highly beneficial new
treatments to help improve the lives of people with epilepsy. The development
of AEDs is a major strategic area for Eisai in Europe, the Middle East,
Africa, Russia and Oceania (EMEA).

In the EMEA region, Eisai currently has four marketed treatments including:

  *Zonegran ^® (zonisamide) as monotherapy and adjunctive therapy in adult
    patients with partial-onset seizures, with or without secondary
    generalisation. (Zonegran is under license from the originator Dainippon
    Sumitomo Pharma). In Switzerland, Zonegran is only approved as adjunctive
    therapy.
  *Zebinix ^® (eslicarbazepine acetate) as adjunctive therapy in adult
    patients with partial-onset seizures, with or without secondary
    generalisation. (Zebinix is under license from BIAL). Zebinix is not
    approved by Swissmedic.
  *Inovelon ^® (rufinamide) for the adjunctive treatment of seizures
    associated with Lennox-Gastaut Syndrome in patients >4 years (Inovelon is
    under license from Novartis Pharma AG)
  *Fycompa ^® (perampanel) for use as an adjunctive treatment for partial
    onset seizures, with or without secondarily generalised seizures, in
    patients with epilepsy aged 12 years and older

About Eisai

Eisai is one of the world's leading research and development (R&D) based
pharmaceutical companies and we define our corporate mission as "giving first
thought to patients and their families and to increasing the benefits health
care provides," which we call human health care ( hhc ).

Eisai concentrates its R&D activities in three key areas:

  *Oncology including: anticancer therapies; tumour regression, tumour
    suppression, antibodies, etc.
  *Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight
    loss
  *Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
    arthritis, psoriasis, inflammatory bowel disease

With operations in the U.S., Asia, Europe and its domestic home market of
Japan, Eisai employs more than 10,000 people worldwide. From its Knowledge
Centre in Hatfield, UK, Eisai has recently expanded its business operations to
include Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA
has sales and marketing operations in over 20 markets, including the United
Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria,
Denmark, Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands,
Belgium, the Middle East and Russia.

For further information please visit our web site http://www.eisai.co.uk

Date of preparation: June 2013 Job code: Corporate-UK2014

Contact: Media Enquiries: Eisai Europe Ltd, Cressida Robson / Charlotte
Andrews, +44(0)7908 314 155 / +44(0)7947 231 513, Cressida_Robson@eisai.net,
Charlotte_Andrews@eisai.net ; Tonic Life Communications: Siobhan Reilly/Fran
Murphy, +44(0)7900 605 652 / +44(0)207 798 9900, Siobhan.Reilly@toniclc.com,
Frances.Murphy@toniclc.com
 
Press spacebar to pause and continue. Press esc to stop.